

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: May Lin Tao, MD MSHS

eRA COMMONS USER NAME (credential, e.g., agency login):

POSITION TITLE: Clinical Associate Professor of Radiation Oncology

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)*

INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	Completion Date MM/YYYY	FIELD OF STUDY
Yale University	BS	05/1988	Biology
New York University (NYU) School of Medicine	MD	05/1992	Medicine
Boston Children's Hospital	PGY 1, 2	05/1994	Pediatric Medicine
University of California, Los Angeles, School of Public Health	MS	05/1996	Health Services Research
Harvard Joint Center for Radiation Therapy (now known as Harvard Radiation Oncology Program)	PGY 2-5	05/1998	Radiation Oncology

Personal Statement

Throughout my career, I have cultivated a diverse and extensive background encompassing academic, clinical practice and service domains. This includes formal training and funded work in health services research, with a particular focus on measuring cancer patient reported outcomes, patient preferences in clinical decision making, and functional outcomes following cancer treatment across pediatric and adult populations. Additionally, I have gained expertise in reporting real-world evidence using diverse data sources such as electronic health records, patient surveys, and tumor registry data to elucidate outcomes in the community setting.

As a principal investigator, I have successfully led my own funded projects, assuming responsibilities such as project administration, research team mentorship, and collaboration resulting in peer-reviewed publications. In conjunction with my research experience, I possess a wealth of clinical practice knowledge acquired through working in a multitude of settings and communities. From hospital-based to free-standing facilities, academic to private institutions, and small to large health systems, I have garnered a wide range of experiences that have further honed my understanding of the healthcare landscape.

Furthermore, my involvement in large network organizations has allowed me to actively contribute to the development and implementation of evidence-based clinical guidelines, thereby improving the

overall quality of care. Recently, I joined Keck Medicine of USC in 2021, where one of my primary roles revolves around launching a community-based comprehensive cancer program through a joint venture between Keck Medicine of USC and Henry Mayo Hospital, a local independent community hospital in Santa Clarita, CA.

Driven by the realization that a significant portion of cancer care takes place within local communities, my research passion lies in optimizing the delivery, quality, and accessibility of complex cancer care in such settings. While scientific breakthroughs for specific disease states often necessitate substantial resources within large academic centers (research laboratories, clinical investigation support teams), my research interests gravitate towards interventions that are generalizable in the community, less resource-intensive, and built upon existing routine care mechanisms. By leveraging data collected during the routine delivery of care, I aim to identify and inform the next level of care, such as implementing tailored cancer screening strategies for at-risk populations.

The recent investments made by Keck Medicine of USC in community-based, multidisciplinary cancer programs done in collaboration with local anchor hospitals present an opportune platform for my research pursuits. By forging novel relationships and capitalizing on existing mechanisms, I am dedicated to developing and testing proactive, self-sustaining recruitment and navigation strategies to expand cancer screening and education efforts. As evidence on cancer prevention and best practices for early detection continues to accumulate, it is essential to bridge the gap between knowledge and implementation. For instance, lung cancer is the leading cause of cancer deaths in the US, regardless of gender or ethnicity. The groundbreaking National Lung Screening Trial demonstrated that annual low-dose CT scans in an at-risk population significantly reduces mortality from lung cancer.¹ However, the utilization rates of low-dose CT screening for eligible patients remain extremely low at single digit percentages across different insurance types.²

My research endeavors are centered around leveraging routine care mechanisms, establishing innovative partnerships and utilizing data driven approaches to drive transformative change in the cancer care delivery within local communities. Through this approach, I strive to make a tangible impact by increasing the rates of cancer screening and implementing evidence-based practices for early detection, ultimately improving patient outcomes and reducing the burden of cancer-related morbidity and mortality in communities.

1. de Koning, Harry, vander Aalst et al. Reduce Lung Cancer Mortality with Volume CT Screening in a Randomized Trial. *New England Journal of Medicine* 2020; 382:503-513. doi:10.1056/NEJMoa1911793
2. Hughes DR, Chen J, Wallace AE, et al. Comparison of lung cancer screening eligibility and use between commercial, Medicare, and Medicare Advantage Enrollees. *J Am Coll Radiol.* 2023;20(4):402-410. doi:10.1016/j.jacr.2022.12.022.

A. Positions, Scientific Appointments, and Honors

(Select) Positions and Scientific Appointments

2022-present	Director of Clinical Operations, Regional Radiation Oncology Clinics, Keck School of Medicine
2021-present	Clinical Associate Profession, Dept. of Radiation Oncology, Keck School of Medicine
2021-present	Medical Director, Keck/USC and Henry Mayo Cancer Program, Santa Clarita, CA
2018-2021	Assistant Clinical Professor, Dept. of Radiation Oncology, City of Hope
2016-2018	Medical Director, Santa Clarita Radiation Oncology, Vantage Oncology, Santa Clarita, CA
2017-2020	Co-Chair Radiation Oncology Clinical Excellence and Pathways Committee, USON/McKesson Specialty Health
2000-2005	Co-Medical Director, Center for Radiation Therapy of Beverly Hills, CA

2010-2018 Board Member Valley Radiotherapy Associates Medical Group (VRAMG)
2008-2010 Founding Member and Medical Director of Radiation Oncology, East Bay Partners in Cancer Care (EPICC), Contra Costa County, CA
2007-2010 Vice Chair, Breast Committee, Quality Research in Radiation Oncology (QRRO), American College of Radiology
2006-2007 Medical Director of Radiation Oncology, St Joseph's Hospital, Orange, CA
2005-2007 Vice Chair Health Service Research Committee, American Society of Therapeutic Radiation Oncology (ASTRO)
2004-2007 Board Member, Southern California Radiation Oncology Society
2000-2007 Director of Clinical Research and Outcomes, VRAMG/Vantage Oncology, Los Angeles, CA
2000-2006 Adjunct Member, John Wayne Cancer Institute, Santa Monica, CA
2000-2005 Adjunct Assistant Professor of Radiation, Dept of Radiation Oncology, UCLA School of Medicine
1999-2000 Co-Medical Director, Pediatric Brain Tumor Program, UCLA Medical Center
1998-2005 Member, Division of Cancer Prevention and Control Research, Jonsson Cancer Center, UCLA School of Medicine
1998-2000 Assistant Professor, Depts. Radiation Oncology and Pediatrics, UCLA School of Medicine

Honors:

2023 Women of Influence: Health care, Los Angeles Business Journal
1997 Merit Award, American Society of Clinical Oncology (ASCO)
1996 Boston Children's Hospital von Meyer Research Award

B. Contributions to Science

1. My early career laid the foundation for my interest and training in developing tools to identify at risk populations, measure functional outcomes and devise interventions to create access to care and improve outcomes. I developed and validated both child and parent reported quality of life surveys for pediatric brain tumor, acute leukemia patients, and breast cancer patients. I had initial career development and Dept. of Defense project funding and published preliminary findings.

Project: Development of A New Brain-Specific Quality of Life Instrument for Pediatric Cancer Patients and Survivors.

Supported by

American Cancer Society (ACS) Career Development Award
Radiological Society of North America (RSNA) Scholar Grant
American Society of Therapeutic Radiation Oncology Outcomes Fellow Award

Related publications/chapters:

Owen JB, Khalid N, Ho A, Kachnic LA, Komaki R, Tao ML, Currey A, Wilson JF. Can patient comorbidities be included in clinical performance measures for radiation oncology? J Oncol Pract. 2014 May; 10(3):e175-81.

Tao ML, Guo MD, Weiss, R, Byrne J, Mills JL, Robison LL, Zeltzer LK. Smoking in Adult Survivors of Childhood Leukemia: A National Institutes of Health and Children's Cancer Group Study. J Natl Cancer Instit. 1998 Jan; 90(3), 219-25.

Tao, ML and Parsons, SK. Quality of Life Assessment in Pediatric Brain Tumor Patients and Survivors: Lessons Learned and Challenges to Face. J Clin Oncol 23(24): 5424-6 (2001).

Malogolowkin MH, Tao ML, Tischler D. Cancer Treatment. 5th Edition. Philadelphia: WB Saunders; c2001. Retinoblastoma; pp. 1198-1204.

Malogolowkin MH, Tao ML, Klipfeld N, Bhuta SM, Atkinson JB. Cancer Treatment, 5th Edition. Philadelphia: WB Saunders; c2001. Wilms' Tumor; pp. 1205-14.

Tao ML, Zeltzer PM, Zeltzer LK. Ambulatory Pediatrics, Fifth Edition. Philadelphia: W.B.Saunders Company; c1999. The Pediatrician's Role with the Child Cancer Patient; pp. 288-295

Tao ML and Ganz PA. Looking Beyond Survival: Assessment of Quality of Life In: Harris, JR, Lippman M, Morrow M, Osbourne CK, editors, Diseases of the Breast, Updates. Philadelphia: Lippincott Williams and Wilkins, 2(4), 1998.

Project: Arm morbidity and Decision-making in Treatment of Breast Cancer

Supported by US Department of Defense (Career Award)

Related publication:

Galper SR, Lee SJ, Tao ML, Troyan S, Kaelin CM, Harris JR, Weeks JC. Patient preferences for axillary dissection in the management of early stage breast cancer. Journal of the National Cancer Institute. 2000 Oct; 92(20):1681-7.

2. Utilizing a process of rapid case ascertainment through the Los Angeles County Cancer Surveillance Program, we were able to identify, survey and track a large group of breast cancer patients over a 2-year period to better understand determinants of care for breast cancer patients including language and cultural factors, nature of physician engagement, structural aspects of the health system and symptom severity. The research team consisted of social science researchers as well as primary care physicians and oncologists in the UCLA Jonsson Cancer Center, Division of Cancer Prevention and Control Research (DCPCR) and RAND Health.

Related publications:

Rose DR, Tisnado DT, Tao ML, Malin JL, Adams JL, Ganz PA, Kahn KL Prevalence, Predictors and Patient Outcomes Associated with Physician Co-management: Findings from Los Angeles Women's Health Study. Health Serv Res. 2012 Jun; 47(3 Pt 1):1091-116.

Rose D, Tisnado D, Malin J, Tao ML, Maggard M, Adams J, Ganz P, Kahn K. Use of Interpreters by Physicians Treating Limited English Proficient Women with Breast Cancer: Results from the Provider Survey of the Los Angeles Women's Health Study. Health Serv Res. 2010 Feb; 45 (1): 172-94.

Chen JY, Malin J, Ganz PQ, Ko C, Tisnado D, Tao ML, Timmer M, Adams JL and Kahn KL. Variation in Physician-patient Discussion of Breast Reconstruction. J Gen Intern Med. 2009 Jan; 24(1):99-104.

Tisnado D, Ganz PA, Tao ML, Malin J, Timmer M, Adams JL, Ko C, Kahn KL. The Structural Landscape of the Health Care System for Breast Cancer: Results from a physician survey. The Breast Journal. 2009 Jan-Feb; 15(1): 17-25.

Chen J, Tao ML, Tisnado D, Malin J, Ko C, Timmer M, Adams JL, Ganz PA, Kahn KL. Impact of Physician-Patient Discussion on Patient Satisfaction. *Med Care*. 2009 Nov; 46(11):1157-62.

Yoon J, Malin J, Tao ML, Tisnado DM, Adams JL, Timmer MJ, Ganz PA, Kahn KL. Symptoms after breast cancer treatment: are they influenced by patient characteristics? *Breast Cancer Res Treat*. 2008, Mar; 108(2):153-6.

3. While a member of large radiation oncology group practice in southern California and partnering with a radiation oncology national network, I published articles on feasibility and outcomes of the delivery of complex cancer treatments and services in the community setting.

Related publications:

McCloskey SA, Tao ML, Rose CM, Fink A, Amadeo A. National Survey of Perspectives of Palliative Radiation Therapy: Role, Barriers, and Needs. *Cancer J*. 2007 Mar-Apr; 13(2):1307

McCloskey SA, Botnick LE, Rose CM, Malcolm AW, Ozohan ML, Mena R, Llamas L, Tao ML. Long-Term Outcomes after Breast Conservation Therapy for Early Stage Breast Cancer in a Community Setting. *The Breast Journal*. 2006 Jul; 12(2):138-44.

Morris DE, Emami B, Mauch PM, Konski AA, Tao ML, Ng AK, Klein EA, Mohideen N, Hurwitz MD, Fraas BA, Roach M 3rd, Gore EM, Tepper JE. Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative. *Int J Radiat Oncol Biol Phys*. 2005 May; 62(1):3-19.

McCloskey SA, Ellerbroek NA, McCarthy L, Malcolm AW, Tao ML, Wollman RC, Rose CM. Treatment outcomes of three-dimensional conformal radiotherapy for localized prostate carcinoma: a large community-based experience. *Cancer*. 2004 Dec; 101(11):2693-700.

Ellerbroek N, Martino S, Mautner B, Tao, ML, Rose C, Botnick L. Breast-conserving therapy with adjuvant paclitaxel and radiation therapy– Feasibility of concurrent treatment. *The Breast Journal*. 2003 Mar; 9(2): 74-78.